London-based AI drug discovery firm Isomorphic Labs has secured $5bn (£3.8bn) in a Series C funding round, marking one of the largest investments in British technology. The Google Deepmind spinout, led by Nobel Prize-winning scientist Sir Demis Hassabis, announced the oversubscribed round on Tuesday, 17 November 2026.
The funding was co-led by US venture capital firms Greenoaks and Sequoia Capital. Other participants included Andreessen Horowitz, Alphabet, Thrive Capital, MGX, GV, Capital G, Temasek, and the UK government’s Sovereign AI Fund. This investment follows a $2.1bn Series B funding round six months prior, bringing total disclosed external funding to approximately $7.7bn since 2025.
Isomorphic Labs, founded in 2021, uses its proprietary drug design engine, 'IsoDDE', to predict how molecules interact with biological targets. This aims to reduce the time and cost associated with drug development. The company is developing its own medicines for cancer and immune disorders, and also has partnerships with pharmaceutical companies such as Eli Lilly, Novartis, and Johnson & Johnson.
Despite raising billions, Isomorphic Labs has not yet commenced human testing of its drug candidates. The company is reportedly in late-stage preclinical development, with early results described as encouraging across its internal oncology and immunology programmes and partnered projects. The new funding is intended to support the development of its AI models, expand its drug pipeline, and build global bioengineering infrastructure as it prepares for clinical trials.
AI minister Kanishka Narayan welcomed the announcement, stating that Isomorphic Labs' work “could fundamentally change how new medicines are discovered and accelerate the development of life-changing treatments for patients around the world.” Sir Demis Hassabis added that the funding will enable the company to accelerate progress in building foundational biology models, deepening systemic disease understanding, and driving therapeutic programs towards clinical trials.